Personalized dosing study for Xa inhibitor blood thinners
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This study looks at how the body processes a certain type of blood thinner (Xa factor inhibitors) to help doctors find the right dose for each person. If you have a blood clot in your lungs and are on long-term treatment, this trial might help improve your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a blood clot in your lungs (pulmonary embolism) using an imaging test.
- You have finished the initial treatment for the clot and are now on long-term blood thinning therapy.
- You are expected to live for more than 3 months.
- Your doctor has approved the use of a type of blood thinner called an Xa factor inhibitor (like apixaban or rivaroxaban).
- You do not have moderate or severe liver disease, severe kidney disease, a bleeding disorder, or antiphospholipid syndrome.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a blood thinner called rivaroxaban (a pill) works well for older Chinese patients who have had a blood clot in their lungs and are now on long-term treatment. It aims to see if it's safe and effective for this group.
This trial compares close monitoring (“watch and wait”) versus taking the blood thinner rivaroxaban in people with a small type of lung blood clot. It aims to find out whether low-risk patients can safely avoid or reduce anticoagulation while still staying healthy.
This study looks at whether a blood test measuring a substance called anti-factor Xa activity can help predict dangerous blood clots in critically ill patients. If you join, researchers will follow you to see if the test results can prevent clots.
This trial looks at how long people need blood-thinning medicine after a serious blood clot in the lungs. It might help doctors find the best treatment length for each person.
This trial tests a treatment that uses ultrasound to guide a thin tube (catheter) to deliver clot-busting medicine directly into the blood clot in your lung. It may be an option for people whose clot is serious but not yet causing shock, and who have symptoms that started within the last two weeks.
This trial compares three treatments for an intermediate-high risk pulmonary embolism: a minimally invasive clot removal procedure (embolectomy), a low-dose clot-dissolving medication, or standard blood thinning (heparin). The goal is to see which approach works best to prevent worsening while reducing bleeding risks.
Hear when a new Pulmonary Embolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.